Journal of the American Veterinary Medical Association
JAVMA Instructions for Authors
June 2021
The Journal of the American Veterinary Medical Association is a semimonthly, peer-reviewed, general veterinary medical journal owned by the American Veterinary Medical Association. The journal publishes manuscripts dealing with any subject germane to the practice of veterinary medicine. Specifically, the mission of the Journal of the American Veterinary Medical Association is to promote the science and art of veterinary medicine and to provide a forum for discussion and dissemination of ideas important to the profession.
EDITORIAL POLICIES
Authorship
Individuals should be listed as authors only if they (1) made a substantial contribution to the conception and design of the study, the acquisition of the data used in the study, or the analysis and interpretation of that data; (2) were involved in drafting or revising the manuscript critically for important intellectual content; and (3) approved the submitted version of the manuscript and will have an opportunity to approve subsequent revisions of the manuscript, including the version to be published. All 3 conditions must be met. Each individual listed as an author must have participated sufficiently to take public responsibility for the work. Acquisition of funding, collection of data, or general supervision of the research team does not, alone, justify authorship. Requests to list a working group or study group in the byline will be handled on a case-by-case basis. All authors must complete and submit the Copyright Assignment Agreement and Authorship Form (jav.ma/CAA-AF), confirming that they meet the criteria for authorship. If a manuscript describes clinical treatments or clinical interpretations, at least 1 author must be a veterinarian.
Commercial availability, compounding, and extralabel drug use
A manuscript reporting results of a study that involved evaluation of the efficacy or safety of a pharmaceutical, biologic, or other product or in which such products were relevant to the diagnosis, treatment, or outcome will be considered only if the product is commercially available in the United States and can legally be used in the species of interest.
Manuscripts describing studies or clinical cases that involved administration of products compounded from bulk substances (eg, regulated under 21 CFR §510 and 21 CFR §511.1) or FDA-approved drug products (eg, regulated under 21 CFR §530) must include an explanation in the Discussion section of why the authors chose to use compounded products and what key factors should be considered by veterinarians interested in prescribing similarly prepared products. Additionally, the Materials and Methods section should contain a complete description of the compounded products, including the identities of the active and inactive ingredients, concentration of each ingredient, and, if available, stability data for each product such that the compounded product may be replicated if needed.
All extralabel drug use must comply with the provisions of the Animal Medicinal Drug Use Clarification Act (jav.ma/AMDUCA).
Examples of the types of statements that would be appropriate for the Discussion section include the following:
• Extralabel drug use was performed with owner consent and complied with provisions of AMDUCA and 21 CFR §530.
• Compounded products were prepared from bulk substances because [provide reason]. Veterinarians should adhere to ompounding regulations and be aware that pharmacokinetic properties may differ between compounded and FDA-approved products.
• Compounded products were prepared from FDA-approved products because [provide reason]. Veterinarians should adhere to compounding regulations and be aware that pharmacokinetic properties may differ between compounded and FDA-approved products.
Conflicts of interest and financial disclosures
A conflict of interest exists whenever an individual has financial interests or personal relationships that might consciously or unconsciously influence their decisions. Conflicts of interest are ubiquitous and cannot be completely eliminated; they do not, by themselves, indicate improper behavior, wrongdoing, or scientific misconduct.
Financial relationships are the most easily identifiable conflicts of interest and include, among other things, ownership, employment, consultancies, honoraria, paid expert testimony, grants, patents, stock ownership or options, and service as an officer or board member. Other conflicts of interest include personal and professional relationships, academic competition, and intellectual beliefs.
All authors must disclose in the Acknowledgments section of the manuscript any financial or personal relationships that could be perceived to influence or could give the appearance of influencing information in the submitted manuscript. This includes detailed information about all relevant financial interests, activities, relationships, and affiliations (other than affiliations listed on the title page of the manuscript) occurring at the present time or within the 3 years prior to manuscript submission. In this context, relevant financial interests, activities, relationships, and affiliations should be interpreted broadly. For example, authors should disclose relationships they have not only with companies that manufacture products that are the subject of research described in the manuscript but also with companies that manufacture competing products. If no such conflicts of interest existed, the following statement or an equivalent should be included: The authors declare that there were no conflicts of interest.
The scientific editors reserve the right to reject any manuscript because of conflicts of interest. Failure to fully disclose conflicts of interest may be grounds for rejection or retraction of the manuscript.
Copyright
The JAVMA is covered by copyright. All authors will be required to transfer copyright to the AVMA prior to publication of any manuscript or letter by completing and submitting the Copyright Assignment Agreement and Authorship Form (jav.ma/CAA-AF). Requests to copy, reprint, or use portions of published material (including information in figures, appendices, and tables) should be addressed to the editor-in-chief.
Authors must obtain and submit a statement of permission from the copyright holder (most often, the author or publisher) if they wish to include an exact duplicate or a slightly modified version of items such as figures, appendices, or tables that appeared or will have appeared in other published reports prior to publication of the manuscript, regardless of the originating source.
Original artwork (eg, drawings or photographs) that was created specifically for use in the manuscript must be accompanied by a letter explaining the conditions under which the work was created. The letter must be signed by the artist and specify the rights given to the authors for use of the artwork and the rights retained by the artist (if any). If rights are retained by the artist, the letter must include a statement that allows the journal to use the material for publication in print and online.
If diagnostic images (eg, radiographic, CT, MRI, and histologic images) that were not prepared by the authors or their institution are included in the manuscript, the authors must include a statement from the copyright holder that allows the journal to use the images for publication in print and online.
Dual-use research of concern
Openness is recognized as a priority when making decisions regarding scientific publishing. Advances in molecular and cellular biology, genetics, microbiology, and other life sciences have made it increasingly possible to manipulate aspects of biological systems to better understand healthy states and mechanisms of disease. However, these advances have also increased the potential that information, products, or technologies resulting from life sciences research may be misused for harmful purposes. The US National Science Advisory Board for Biosecurity has proposed the following definition for dual-use research:
Dual-use research of concern is research that, based on current understanding, can be reasonably anticipated to provide knowledge, products, or technologies that could be directly misapplied by others to pose a threat to public health, safety, agricultural crops and other plants, animals, the environment, or material.
Accordingly, the JAVMA has adopted the following policy regarding assessment of submitted manuscripts with potential dual-use content:
……
更多详情：
https://www.avma.org/sites/default/files/2021-06/javma-ifa.pdf
